500-Million-Year-Old Fossil Suggests Ocean Origin For Spiders
A fresh look at a 500-million-year-old fossil by researchers from the University of Arizona and Lycoming College in the US and King's College London has revealed remarkable similarities between the brains of extinct marine arthropods and modern-day arachnids.
The discovery wades into controversial territory regarding the evolutionary origin of spiders and their relatives.
Today, spiders, scorpions, mites, and ticks are virtually all terrestrial, and the prevailing view is that these arachnids evolved from a common, land-dwelling ancestor.
Related:
Where that ancestor came from is a whole other mystery. Arachnids on land are related to other 'chelicerates' in the ocean, like sea spiders and horseshoe crabs, but the fossil record is very patchy.
"It is still vigorously debated where and when arachnids first appeared, and what kind of chelicerates were their ancestors, and whether these were marine or semi-aquatic like horseshoe crabs," explains University of Arizona neuroscientist Nicholas Strausfeld.
The transition from sea to land is a big step for a little creature, no matter how many legs it has.
The oldest accepted remains of an arachnid are of a 430-million-year-old scorpion, a critter that lived on land. But new evidence suggests that arachnids as a whole may have started to diverge from other chelicerates long before that.
On the outside, Mollisonia symmetrica may not look very 'spidery'. It kind of resembles a pillbug with a bunch of little legs, and previously, it was thought to be an ancestor of horseshoe crabs.
Using light microscopy, researchers have now imaged the fossil's central nervous system and come across an unexpected find.
The nervous system of Mollisonia doesn't resemble that of a horseshoe crab or even a crustacean or insect. Instead, the pattern of radiating neural centers was flipped backward, like that of an arachnid.
"The arachnid brain is unlike any other brain on this planet," explains Strausfeld.
In the Mollisonia fossil, the unique nervous system seems to innervate numerous legs, as well as two pincer-like mouth parts, where modern spiders now have fangs.
"This is a major step in evolution, which appears to be exclusive to arachnids," says evolutionary neuroscientist Frank Hirth from King's College London.
"Yet already in Mollisonia, we identified brain domains that correspond to living species… "
That seems to be no coincidence. Upon further statistical analysis, Hirth and colleagues have found that arachnids probably didn't evolve similar structures to Mollisonia by accident; they were more likely inherited.
If the team is right, that puts Mollisonia at the base of the arachnid lineage, making it a sister to horseshoe crabs and sea spiders.
While still speculative, it's possible that the unique brain structure seen in the Mollisonia lineage helped its later successors survive on land.
Neural 'shortcuts' to the legs and pincers, for instance, could make it easier to control and coordinate complex movements, like walking or weaving webs.
"We might imagine that a Mollisonia-like arachnid also became adapted to terrestrial life making early insects and millipedes their daily diet," theorizes Strausfeld.
Perhaps it was the earliest arachnids on land that first drove insects to evolve wings and hence flight – and maybe, in turn, airborne prey led to the evolution of webs.
From the ocean floor to the treetops, the way that arachnids have adapted to the changing times is truly enviable.
The study was published in Current Biology.
Related News
Secret Bone Armor Discovered Beneath Skins of Australian Lizards
Many Butterflies Have a Second 'Head' – This Could Be Why
Your Dog May Prefer Certain TV Shows, Research Suggests
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials
CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026 CARB-X's additional funding brings their financial support to date for the Alphamer platform and lead compound non-clinical development to $12.3M ALDERLEY PARK, England, July 29, 2025--(BUSINESS WIRE)--Centauri Therapeutics Limited ('Centauri' or 'the Company'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri's ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X's total support from 2019 to date to $12.3M. Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 20251. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the Company's proprietary Alphamer® platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound's activity against Gram-negative bacteria. "The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies," said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. "We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients." Dr. Erin Duffy, Chief of Research and Development, CARB-X, commented: "We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials." CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. Press Release (4th March, 2025): Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections View source version on Contacts Media contact Katie OdgaardEmail: Tel: +44 (0) 7787 502 947 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
9 hours ago
- Medscape
Preterm Birth Predicts Adult Health Problems
Adults born preterm were significantly more likely to have cardiometabolic risk factors and internalized mental health issues than full-term peers, according to an ongoing preterm birth cohort study in the US. 'This study addresses a significant gap in understanding the long-term health effects of preterm birth in the US,' said lead author Amy D'Agata, PhD, of the College of Nursing, The University of Rhode Island, Kingston, Rhode Island, in an interview. Although the annual preterm birth rate in the US has held at a relatively stable 10%-12% for decades, since the 1970s, more preterm infants are surviving because of advances in neonatal intensive care, D'Agata said. Millions of individuals born preterm are aging into adulthood, but few data are available on their long-term health outcomes, she noted. In the new study, published in JAMA Network Open , D'Agata and colleagues reviewed data from a cohort of individuals who received level III neonatal intensive care at a single center between 1985 and 1989. The study population included 158 preterm-born and 55 full-term born adult control individuals. Preterm was defined as weighing under 1850 g at birth with various neonatal diagnoses; critically ill infants and those with major congenital abnormalities were excluded. The mean age across the groups was 35 years; 50% were women. The researchers used latent growth curve models to show changes over time. Overall, the preterm individuals who had higher medical risk in early life were significantly more likely to have a range of health problems at 35 years of age, notably, higher triglycerides than control individuals (beta value, 53.97; P = .03). Measures of systolic blood pressure and central adiposity also were significantly higher in the preterm birth group (beta values of 7.15 and 0.22, respectively), whereas bone density and high-density lipoprotein cholesterol were lower (beta values of -1.14 and -13.07, respectively). In addition, internalizing mental health problems were significantly more common in the preterm cohort than in the control individuals (beta value, 0.85; P = .01) but no difference in externalizing mental health problems was noted between the groups. The researchers also reviewed the impact of social protection and childhood socioeconomic status and found no association between these and physical or psychological health risks in adults born preterm. The Long View of Preterm Birth The population of adults born preterm remains largely invisible to the US healthcare system and its clinicians, highlighting critical issues of health equity and quality of care, D'Agata told Medscape Medical News . 'Much of the existing research in this area has focused on international, homogeneous populations, creating a need for rigorous, US-based longitudinal data to guide healthcare policy and clinical practice,' she added. 'These findings generally confirmed what has been observed internationally, that there is a link between higher early life medical risk and increased likelihood of mental health issues, elevated systolic blood pressure, unfavorable cholesterol and triglyceride levels, body fat distribution, and lower bone density among adults born preterm, and it was notable to see these clear and consistent associations replicated in a US cohort using a prospective, longitudinal design,' said D'Agata. The study findings emphasized the need to inquire about birth history in adult care settings and suggest that those born preterm and their families must be their own health advocates, if necessary, said D'Agata. 'Even if a patient isn't asked about their birth history, they should share it,' she noted. Clinicians work hard to provide the best care, but it takes time for evidence-based research to inform clinical practice, she said. 'Although our birth cohort is small and comes from a single geographic region, the results generally align with international findings,' D'Agata told Medscape Medical News . However, future studies should include more racially and ethnically diverse cohorts from multiple clinical settings, she said. Research is needed not only to examine which subgroups of preterm individuals are most at risk but also to differentiate between those with varying degrees of early life complications, she added. Long Follow-Up Strengthens Findings The 35-year duration of the preterm birth cohort study was impressive and valuable, said Tim Joos, MD, a clinician with a combination internal medicine/pediatrics practice at Neighborcare Health in Seattle. 'We don't often have the long game in mind, in healthcare as well as in other parts of our society,' said Joos, who was not involved in the study. 'We don't tend to follow pediatric conditions into adulthood,' he noted. The current study findings demonstrated a long-term psychological and physical impact of prematurity on adult health that was humbling, Joos told Medscape Medical News . Looking ahead, the results highlight not only the need to continue to prevent preterm birth but also to the importance of asking older patients about preterm birth as part of their health history, he said.
Yahoo
11 hours ago
- Yahoo
LIfT BioSciences announces grant of €12 million from Ireland's Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT's IMAN therapy
Galway, London, 29 July 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland's Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026. The €12 million grant, the largest grant awarded by the DTIF to date, was awarded to a consortium LIfT formed with the University of Galway, renowned for their expertise in cell therapy development, innovation, and clinical trials and Hooke Bio, pioneers of a novel immuno-analytics platform designed to enhance therapy response rates, as part of the Company's grant application process. The funding will be used to conduct an investigator initiated clinical trial designed to test the feasibility and safety of IMAN therapy administered to patients with metastatic cervical cancer or head and neck cancer who have exhausted all standard treatment options, including checkpoint inhibitors. Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: 'The grant awarded from DTIF is a significant milestone for LIfT as we expand our presence in Ireland and advance toward closing the second round of our Series A financing. By combining LIfT's innovative immunotherapy platform with the University of Galway's deep expertise in oncology, patient care, and advanced manufacturing, and Hooke Bio's analytical expertise, we are enhancing our clinical-stage research and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.' Commenting on the award, Peter Burke, Minister for Enterprise, Tourism and Employment, said that 'The Government established the Disruptive Technologies Innovation Fund to invest in technologies that demonstrate true innovation and with the potential to address critical national and societal challenges. We want to fund projects that will make a real difference to people's lives. The N-LIfT project has come through a rigorous evaluation process and the level of funding awarded reflects its potential to be a game-changer in cancer therapy. I'm excited to see the impact it will deliver.' The trial will test progressively higher IMAN doses in sequential patient cohorts to determine the biologically active dose. It will then be expanded to additional patients who will be infused with IMANs at the previously determined recommended dose in combination with checkpoint inhibitor therapy. The results of this evaluation will help bring this promising technology to cancer patients faster and enable LIfT to attract additional investment into Ireland for its ongoing clinical and manufacturing programme in Galway. Dr Michael McCarthy, Consultant Medical Oncologist and Principal Investigator at University Hospital Galway added: 'Cancer remains one of the most complex and dynamic diseases. IMANs have the potential to overcome key limitations of current cancer treatments by activating both the innate and adaptive branches of the immune system. This dual stimulation enables a comprehensive anti-tumour response, representing a transformative advancement in cancer therapy. We are pleased to receive this grant in collaboration with LIfT and Hooke Bio, and we look forward to accelerating the clinical development of this groundbreaking immunotherapy.' Professor Sean Hynes, Consultant Histopathologist and Translational Cancer Researcher from the School of Medicine and Lead Academic on the award commented: 'In partnership with LIfT Biosciences and Hooke Bio, we are very excited about the University of Galway and Galway University Hospital being at the forefront of delivering on new oncological cellular therapies by using neutrophils, the body's own first responders, in the fight against cancer and ensuring patients in the West of Ireland have access to such cutting edge treatments.' Mark Lyons, Ph.D., CEO at Hooke Bio added: 'We're very excited to be able to employ our Mera body on a plate platform to support the development of LIfT's immuno-oncology therapeutic. This project highlights the strength of the Irish clinical research eco system and the power of collaboration.' DTIF is a €500 million challenge-based fund established under Project Ireland 2040. It is one of four funds set up under the National Development Plan (NDP) 2018-2027. It is managed by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland. The DTIF fund is for clients of Enterprise Ireland, Údarás na Gaeltachta, IDA Ireland and research performing organisations in Ireland that are collaborating on industrial research and / or experimental development in highly innovative projects. LIfT, registered as Eolaíocht Bhitheach LIfT Teoranta, has a base in An Spidéal, Co. Galway at (gteic@An Spidéal) and, as an Údarás na Gaeltachta client, has been supported by them to create employment in the Gaeltacht. About LIfT BioSciencesLIfT BioSciences is a UK and Ireland-based biotech pioneering a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by restoring immune competence. Its Immuno-Modulatory Alpha Neutrophils (IMANs) recognise and destroy cancer cells through advanced threat pattern recognition in a non-antigen-specific manner. Clinical studies show that this class of neutrophils can prevent tumour escape—responsible for over 90% of cancer-related deaths—by delivering a durable, total immune response and lasting immunity. LIfT's patented N-LIfT platform is derived from exceptional donor stem cells cultured in a proprietary enhancement media, enabling scalable and potent cell production. The company is also advancing iPSC technology and genetic engineering to create next-generation IMAN therapies with pharma partners to achieve cost-effective, long-term remission for cancer patients and beyond. LIfT is currently completing its 2nd close on its Series A Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@